Supplementary Balance Sheet Information

6 Months Ended

Jun. 30, 2022

Balance Sheet Related Disclosures [Abstract]

Note 5 – Supplementary Balance Sheet Information

Property and equipment consist of the following (in thousands):


	June 30, 2022			December 31, 2021
Lab equipment	$	6,725		$	6,784
Leasehold improvements		2,365			2,339
Computer equipment		703			700
Furniture and fixtures		341			391
Software		325			600
Vehicles		97			97
Construction in process		411			17
		10,967			10,928
Less: accumulated depreciation		(7,017	)		(6,749	)
Total property and equipment, net	$	3,950		$	4,179

Depreciation expense for the three and six months ended June 30, 2022 was $0.4 million and $0.8 million, respectively, compared to $0.2 million and $0.5 million for the three and six months ended June 30, 2021, respectively.

Intangible assets, excluding goodwill, consist of the following (in thousands):


	June 30, 2022							December 31, 2021
	Cost		Accumulated Amortization			Net Carrying Value		Cost		Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization
Patents	$	1,785	$	(599	)	$	1,186	$	1,755	$	(566	)	$	1,189
Purchased technology		16,900		(7,512	)		9,388		16,900		(6,572	)		10,328
Intangible assets not subject to amortization
Trademarks		114		—			114		100		—			100
Total	$	18,799	$	(8,111	)	$	10,688	$	18,755	$	(7,138	)	$	11,617

Amortization expense related to definite-lived intangible assets was $0.5 million and $1.0 million for both the three and six months ended June 30, 2022 and 2021, respectively.

Future estimated amortization expense of intangible assets is (in thousands):


	As of June 30, 2022
Remainder of 2022	$	986
2023		1,970
2024		1,960
2025		1,954
2026		1,941
2027 and thereafter		1,763
Total	$	10,574

Accrued liabilities consist of the following (in thousands):


	June 30, 2022		December 31, 2021
Compensation related accruals	$	3,570	$	4,029
Accrued clinical trial expense		908		870
Other expenses		2,189		2,766
Total accrued liabilities	$	6,667	$	7,665